Precigen Inc (PGEN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Precigen Inc stock (PGEN) is currently trading at $3.10. Precigen Inc PS ratio (Price-to-Sales) is 175.54. Analyst consensus price target for PGEN is $8.25. WallStSmart rates PGEN as Sell.
- PGEN PE ratio analysis and historical PE chart
- PGEN PS ratio (Price-to-Sales) history and trend
- PGEN intrinsic value — DCF, Graham Number, EPV models
- PGEN stock price prediction 2025 2026 2027 2028 2029 2030
- PGEN fair value vs current price
- PGEN insider transactions and insider buying
- Is PGEN undervalued or overvalued?
- Precigen Inc financial analysis — revenue, earnings, cash flow
- PGEN Piotroski F-Score and Altman Z-Score
- PGEN analyst price target and Smart Rating
Precigen Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Precigen Inc (PGEN) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Precigen Inc (PGEN) Key Strengths (1)
63.49% held by institutions, strong professional interest
Supporting Valuation Data
Precigen Inc (PGEN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 175.5x annual revenue
Very expensive at 27.7x book value
Small-cap company with higher risk but more growth potential
Solid revenue growth at 19.40% per year
Supporting Valuation Data
Precigen Inc (PGEN) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (175.54), Price/Book (27.72) suggest expensive pricing. Growth concerns include Revenue Growth at 19.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -668.00%, Operating Margin at -3254.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -668.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 19.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PGEN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PGEN's Price-to-Sales ratio of 175.54x sits near its historical average of 191.16x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 17% below its historical high of 212.55x set in Mar 2026, and 0% above its historical low of 175.54x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~212.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Precigen Inc (PGEN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Precigen Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 4M with 19% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 285% of revenue (12M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -29M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Precigen Inc.
Bottom Line
Precigen Inc offers an attractive blend of growth (19% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Precigen Inc(PGEN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.